Research progress on the relationship between antiplatelet drugs and cerebral microbleeds

VernacularTitle:抗血小板药物与脑微出血相关性研究进展
Author: Haichao FU ¹ ; Chao BAN ; Hui ZHANG ; Lihong GE
Author Information

1. 内蒙古医科大学附属医院影像诊断科，呼和浩特　010059
Keywords: Cerebral hemorrhage; Cerebral microbleeds; Antiplatelet drugs
From: Chinese Journal of Neurology 2021;54(8):866-870
CountryChina
Language:Chinese
Abstract: Cerebral microbleeds (CMBs) are a subclinical terminal microvascular disease in which the blood exudates or leaks out from the tiny blood vessels and the small lesions were formed by the deposition of hemosiderin in the brain tissue. The pathogenesis of cerebral microbleeds is different depending on the location, with lobar CMBs attributed to cerebral amyloid angiopathy (CAA), while cerebrovascular diseases caused by hypertension are an important cause of deep and subtentorium CMBs. The prevalence of CMBs in stroke patients is high, especially in patients with ischemic stroke treated with oral antiplatelet drugs, and long-term (>5 years) treatment may be related to CMBs and intracerebral hemorrhage (ICH) events. At the same time, a certain burden of microbleeds may cause risk of ICH in the future, but whether the bleeding risk of antiplatelet treatment overweighs the clinical benefit of antithrombotic therapy remains unclear. How to better instruct antiplatelet therapy in patients with ischemic stroke warrants further clinical investigations.